COMPASS PATHWAYS PLC Comprehensive Income
COMPASS PATHWAYS PLC (CMPS) reported Comprehensive Income of -$253.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$253.74M.
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $91.20M.
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$93.48M.
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$138.32M.
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$286.46M.
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$154.39M.
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$118.52M.
- COMPASS PATHWAYS PLC comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$117.21M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$253.74M 10-Q · filed 2026-08-05 | -$162.54M 10-Q · filed 2026-08-05 | -$256.02M derived: sum of 3 quarters · filed 2026-08-05 | -$394.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $91.20M 10-Q · filed 2026-05-13 | -$2.28M derived: sum of 2 quarters · filed 2026-05-13 | -$140.61M derived: sum of 3 quarters · filed 2026-05-13 | -$177.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$93.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$231.80M derived: sum of 2 quarters · filed 2026-03-24 | -$268.48M derived: sum of 3 quarters · filed 2026-08-05 | -$286.46M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$138.32M 10-Q · filed 2025-11-04 | -$175.00M derived: sum of 2 quarters · filed 2026-08-05 | -$192.98M 10-Q · filed 2025-11-04 | -$235.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$36.67M 10-Q · filed 2026-08-05 | -$54.66M 10-Q · filed 2026-08-05 | -$97.64M derived: sum of 3 quarters · filed 2026-08-05 | -$135.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$17.98M 10-Q · filed 2026-05-13 | -$60.97M derived: sum of 2 quarters · filed 2026-05-13 | -$99.13M derived: sum of 3 quarters · filed 2026-05-13 | -$137.15M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$42.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$81.15M derived: sum of 2 quarters · filed 2026-03-24 | -$119.17M derived: sum of 3 quarters · filed 2026-03-24 | -$154.39M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$38.16M 10-Q · filed 2025-11-04 | -$76.18M derived: sum of 2 quarters · filed 2025-11-04 | -$111.41M 10-Q · filed 2025-11-04 | -$143.40M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$38.02M 10-Q · filed 2025-07-31 | -$73.24M 10-Q · filed 2025-07-31 | -$105.23M derived: sum of 3 quarters · filed 2025-07-31 | -$139.36M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | -$35.22M 10-Q · filed 2025-05-08 | -$67.22M derived: sum of 2 quarters · filed 2025-05-08 | -$101.34M derived: sum of 3 quarters · filed 2025-05-08 | -$128.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$31.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$66.12M derived: sum of 2 quarters · filed 2025-02-27 | -$93.74M derived: sum of 3 quarters · filed 2025-02-27 | -$118.52M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$34.13M 10-Q · filed 2024-10-31 | -$61.74M derived: sum of 2 quarters · filed 2024-10-31 | -$86.53M 10-Q · filed 2024-10-31 | -$103.68M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$27.62M 10-Q · filed 2024-08-01 | -$52.40M 10-Q · filed 2024-08-01 | -$69.55M derived: sum of 3 quarters · filed 2024-08-01 | -$103.08M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$24.79M 10-Q · filed 2024-05-08 | -$41.94M derived: sum of 2 quarters · filed 2024-05-08 | -$75.46M derived: sum of 3 quarters · filed 2024-05-08 | -$113.63M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$17.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$50.68M derived: sum of 2 quarters · filed 2024-02-29 | -$88.85M derived: sum of 3 quarters · filed 2024-02-29 | -$117.21M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$33.53M 10-Q · filed 2023-11-02 | -$71.70M derived: sum of 2 quarters · filed 2023-11-02 | -$100.06M 10-Q · filed 2023-11-02 | -$124.69M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$38.17M 10-Q · filed 2023-08-03 | -$66.53M 10-Q · filed 2023-08-03 | -$91.16M derived: sum of 3 quarters · filed 2024-02-29 | -$115.41M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$28.36M 10-Q · filed 2023-05-11 | -$52.99M derived: sum of 2 quarters · filed 2024-02-29 | -$77.24M derived: sum of 3 quarters · filed 2024-02-29 | -$95.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$24.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$48.88M derived: sum of 2 quarters · filed 2024-02-29 | -$66.76M derived: sum of 3 quarters · filed 2024-02-29 | -$77.49M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$24.25M 10-Q · filed 2022-11-03 | -$42.13M derived: sum of 2 quarters · filed 2022-11-03 | -$52.86M 10-Q · filed 2022-11-03 | -$60.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$17.88M 10-Q · filed 2022-08-04 | -$28.61M 10-Q · filed 2022-08-04 | -$36.51M derived: sum of 3 quarters · filed 2023-02-28 | -$48.39M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$10.73M 10-Q · filed 2022-05-10 | -$18.62M derived: sum of 2 quarters · filed 2023-02-28 | -$30.51M derived: sum of 3 quarters · filed 2023-02-28 | -$47.45M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$7.90M derived: 10-K 12 month − 6-K 9 month · filed 2023-02-28 | -$19.78M derived: sum of 2 quarters · filed 2023-02-28 | -$36.72M derived: sum of 3 quarters · filed 2023-02-28 | -$45.65M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$11.89M 6-K · filed 2021-11-09 | -$28.82M derived: sum of 2 quarters · filed 2021-11-09 | -$37.76M 6-K · filed 2021-11-09 | |
| 2020-06-30 | -$16.93M 6-K · filed 2021-08-11 | -$25.87M 6-K · filed 2021-08-11 | ||
| 2019-12-31 | -$19.27M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |